Objective: This study aimed to explore the link between dietary vitamin C intake and hyperuricemia/gout, utilizing Mendelian randomization to assess causality. Methods: We analyzed cross-sectional data from the National Health and Nutrition Examination Survey (2007-2018) to investigate the association. Mendelian randomization studies, using genetic data from genome-wide association surveys, were conducted to infer causality between vitamin C intake and hyperuricemia/gout. The weighted logistic regression analysis and the instrumental variable based on the inverse-variance weighting served as the primary analytical tool, with sensitivity analyses to ensure robustness. Results: After adjusting for covariates, a stable association was observed between vitamin C intake and hyperuricemia/gout risk. Those consuming >111.75 mg of vitamin C generally had a lower risk. Vitamin C intake recommendations of 75-525 mg and 75-225 mg appeared effective for hyperuricemia and gout, respectively. Mendelian randomization analysis revealed a negative association between vitamin C intake and hyperuricemia (OR = 0.985, 95% CI = 0.973-0.997, p = .015) and gout (OR = 0.857, 95% CI = 0.797-0.921, p < .001). Reverse Mendelian randomization indicated no reverse causality. Conclusion: We hypothesize that a dietary vitamin C intake of 75-525 mg or 75-225 mg may reduce the risk of hyperuricemia and gout, respectively. Further research with larger samples is required to confirm this.